It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
A multitargeted strategy to treat the consequences of ischemia and reperfusion (IR) injury in acute myocardial infarction may add cardioprotection beyond reperfusion therapy alone. We investigated the cardioprotective effect of mild hypothermia combined with local ischemic preconditioning (IPC) or remote ischemic conditioning (RIC) on IR injury in isolated rat hearts. Moreover, we aimed to define the optimum timing of initiating hypothermia and evaluate underlying cardioprotective mechanisms. Compared to infarct size in normothermic controls (56 ± 4%), mild hypothermia during the entire or final 20 min of the ischemic period reduced infarct size (34 ± 2%, p < 0.01; 35 ± 5%, p < 0.01, respectively), while no reduction was seen when hypothermia was initiated at reperfusion (51 ± 4%, p = 0.90). In all groups with effect of mild hypothermia, IPC further reduced infarct size. In contrast, we found no additive effect on infarct size between hypothermic controls (20 ± 3%) and the combination of mild hypothermia and RIC (33 ± 4%, p = 0.09). Differences in temporal lactate dehydrogenase release patterns suggested an anti-ischemic effect by mild hypothermia, while IPC and RIC preferentially targeted reperfusion injury. In conclusion, additive underlying mechanisms seem to provide an additive effect of mild hypothermia and IPC, whereas the more clinically applicable RIC does not add cardioprotection beyond mild hypothermia.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Aarhus University Hospital, Department of Cardiology, Aarhus N, Denmark (GRID:grid.154185.c) (ISNI:0000 0004 0512 597X)
2 Aarhus University Hospital, Department of Forensic Medicine, Aarhus, Denmark (GRID:grid.154185.c) (ISNI:0000 0004 0512 597X)
3 Duke-National University of Singapore Medical School, Cardiovascular & Metabolic Disorders Program, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); National Heart Research Institute Singapore, National Heart Centre, Singapore, Singapore (GRID:grid.419385.2) (ISNI:0000 0004 0620 9905); Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431); University College London, The Hatter Cardiovascular Institute, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201); Asia University, Cardiovascular Research Center, College of Medical and Health Sciences, Taichung City, Taiwan (GRID:grid.252470.6) (ISNI:0000 0000 9263 9645)